Yale School of Management

Harvard University

CEO at SynAgile Corporation

Nitrome Biosciences is developing drugs against a new class of enzymes, initially targeting Parkinson’s disease. When successful, we will have found and characterized a new class of enzymes and will have a proprietary development path for disease-modifying drugs for multiple aging-dependent diseases. Led the Board from establishment of the company through completion of the $38 million Series A financing.

Nitrome Biosciences

Chairman Of The Board

Founded and led company developing a new levodopa/carbidopa delivery system for treatment of Parkinson’s disease. Successfully completed product development, engineering, and in-house scale up to capacity of >100,000 devices/year on a fully custom manufacturing line. Ran a Phase 2 clinical trial demonstrating superior safety and efficacy to all current PD therapies.

SynAgile Corporation

Cofounder, CEO and Chairman

Israel-based venture capital firm focused on medical technology and devices.

7 Health Ventures

Venture Partner

Startup that developed an automated blood glucose analyzer for use in critical care areas of hospitals.

IntelliDx

Chairman

Develops, makes, and sells a line of novel coronary and peripheral balloon angioplasty catheters

•	Led the company through its product development, successful European and US PMA clinical trials, CE mark and FDA approval, and European product launch.
•	Took company from paper concept to product launch in less than 2.5 years while using less than $10M.
•	Raised $16.5M in seed and venture capital.
•	Company ultimately acquired for $230 million cash plus additional milestone payments (2014).

AngioScore

Develops, manufactures, and sells glucose monitors for people with diabetes
Cofounder and Director
1999–2002	Vice President, Business Development
1997–1999	Vice President, Marketing
1995–1997	President & CEO

•	Revenues grew from $5M in 2000 to over $270M in 2003.
•	Went public in 2001 at a $700M valuation and was acquired by Abbott Laboratories in 2004 for $1.2 billion.
•	Product line continues to generates >$500M annual revenue.
•	Raised Series A venture capital funding and participated in all subsequent equity financings, raising $240M.
•	Managed early R&D team that conceived and demonstrated Company’s FreeStyle technology, and marketing team that set product design and specifications.
•	Wrote, in-licensed, managed, and prosecuted Company’s intellectual property portfolio of over 50 issued US patents that were asserted against six competitors.
•	Coinventor on over 40 issued US patents related to glucose monitoring.
•	Negotiated Company’s successful European and Japanese distribution partnerships.
•	Evaluated new diagnostic technologies and market opportunities.

Ephraim Heller